A recent study has scrutinized the financial viability of using a combination therapy involving talazoparib and enzalutamide for treating metastatic castration-resistant prostate cancer (mCRPC) in the United States. The research delves into whether tailoring treatments based on homologous recombination repair (HRR) gene alterations is a cost-effective strategy for healthcare payers.
The study employed a partitioned survival model to predict outcomes for hypothetical mCRPC patients, comparing three distinct treatment approaches. This analysis focused on direct medical costs, life-years gained, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER).
Evaluating Treatment Strategies
Three primary treatment regimens were assessed: first, administering talazoparib plus enzalutamide solely to patients with HRR-deficient tumors while reserving enzalutamide alone for non-HRR-deficient cases; second, offering the combination therapy universally without considering HRR status; and third, providing enzalutamide alone to all patients regardless of HRR status.
Cost-Effectiveness Analysis
The empirical enzalutamide-only strategy emerged as the least expensive, delivering 2.4764 QALYs at a cost of $752,383. In comparison, the HRR-guided combination therapy provided 2.6490 QALYs at $878,517, and universal combination therapy offered 2.8418 QALYs at $1,201,221. However, both combination approaches surpassed the accepted willingness-to-pay threshold of $100,000 per QALY, rendering them economically unviable options.
Key factors influencing these findings include:
- High costs of talazoparib and enzalutamide medications.
- The limited incremental benefits in QALYs relative to the substantial price increases.
Sensitivity analyses reinforced these outcomes, highlighting that even slight reductions in drug prices would be insufficient to bring the combination therapies within the cost-effectiveness threshold.
HRR-guided talazoparib plus enzalutamide therapy does not present a financially sustainable option for mCRPC patients from the perspective of U.S. payers. The combination therapy’s high costs relative to its benefits make it an impractical choice under current pricing structures, indicating the need for alternative strategies or drug pricing adjustments to enhance economic viability.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
